PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW

Prenetics Global Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$19.02+0.50 (+2.70%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Feb 18, 2026	Before market open	$36.60M	$-1.75	–
Q4 FY2024 Ended Dec 31, 2024	Mar 5, 2025	Before market open	$10.50M	–	–
Q4 FY2023 Ended Dec 31, 2023	Apr 1, 2024	Before market open	$5.40M	$-1.57	–

Company guidance

Outlook given with results on Feb 18, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
Adjusted EBITDA lossnon-GAAP	full year 2026	$16.00M to $20.00M	New
IM8 gross margins	2026	60%	New
IM8 revenue guidance	full year 2026	$180.00M to $200.00M	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Prenetics Global filed with the SEC

Oct 13, 2026, 6:53 AM ET
Photo: IM8 co-founder David Beckham; two-time NBA champion Chris Bosh; IM8 chief of staff and brand partnerships Samantha Kwok; and NBA executives (Credit: NBA)
EX-99.1 to Form 6-K
Aug 26, 2026, 8:40 AM ET
Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
EX-99.1 to Form 6-K
Aug 20, 2026, 10:32 AM ET
Prenetics’ IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
EX-99.1 to Form 6-K
Aug 18, 2026, 7:40 AM ET
Prenetics’ IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond
EX-99.1 to Form 6-K
Aug 18, 2026, 7:40 AM ET
Shareholder Letter — Q2 2026
EX-99.2 to Form 6-K
Aug 18, 2026, 7:40 AM ET
Q2 2026 Investor Presentation 1
EX-99.3 to Form 6-K
Aug 17, 2026, 9:08 AM ET
Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
EX-99.1 to Form 6-K
Aug 7, 2026, 8:51 AM ET
RISK FACTORS RELATING TO GENERAL CATALYST FINANCING ARRANGEMENT
EX-99.1 to Form 6-K
Aug 7, 2026, 8:51 AM ET
Dated as of July 13, 2026
EX-99.2 to Form 6-K
Aug 7, 2026, 8:51 AM ET
Dated as of July 13, 2026
EX-99.3 to Form 6-K
Jul 14, 2026, 1:25 PM ET
Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)
EX-99.1 to Form 6-K
Jul 14, 2026, 1:25 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Jun 10, 2026, 8:37 AM ET
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue
EX-99.1 to Form 6-K
Jun 4, 2026, 8:32 AM ET
Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
EX-99.1 to Form 6-K
May 20, 2026, 8:07 AM ET
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
EX-99.1 to Form 6-K
May 14, 2026, 8:10 AM ET
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
EX-99.1 to Form 6-K
May 14, 2026, 8:04 AM ET
Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
EX-99.1 to Form 6-K
May 7, 2026, 8:33 AM ET
Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
EX-99.1 to Form 6-K
Apr 2, 2026, 9:06 AM ET
Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
EX-99.1 to Form 6-K
Mar 6, 2026, 8:07 AM ET
Prenetics Authorizes $40 Million Share Repurchase Program
EX-99.1 to Form 6-K
Mar 3, 2026, 8:47 AM ET
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
EX-99.1 to Form 6-K
Feb 18, 2026, 9:28 AM ET
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR 1 in 12 Months, Revenue Surges 480% YoY
EX-99.1 to Form 6-K
Feb 17, 2026, 4:33 PM ET
Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
EX-99.1 to Form 6-K
Feb 17, 2026, 8:29 AM ET
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
EX-99.1 to Form 6-K
Jan 6, 2026, 8:03 AM ET
Prenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million
EX-99.1 to Form 6-K
Jan 5, 2026, 8:20 AM ET
Prenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation
EX-99.1 to Form 6-K
Dec 30, 2025, 8:22 AM ET
Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8
EX-99.1 to Form 6-K
Dec 23, 2025, 11:21 AM ET
Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure
EX-99.1 to Form 6-K
Dec 11, 2025, 8:38 AM ET
Unit 703-706, K11 Atelier King’s Road,
EX-99.1 to Form 6-K
Nov 24, 2025, 7:40 AM ET
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
EX-99.1 to Form 6-K
Nov 10, 2025, 7:29 AM ET
Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR 1 by December 2025, Fastest Supplement Brand Growth in Industry History
EX-99.1 to Form 6-K
Oct 28, 2025, 3:22 PM ET
Prenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
EX-99.1 to Form 6-K
Oct 27, 2025, 10:45 AM ET
Prenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
EX-99.1 to Form 6-K
Oct 27, 2025, 9:46 AM ET
Prenetics Announces $48 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
EX-99.1 to Form 6-K
Oct 24, 2025, 8:32 PM ET
Prenetics Global Limited Announces Proposed Public Offering
EX-99.1 to Form 6-K
Sep 12, 2025, 8:33 AM ET
Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End
EX-99.1 to Form 6-K
Aug 22, 2025, 7:46 AM ET
Unaudited pro forma condensed financial statements
EX-99.1 to Form 6-K
Aug 1, 2025, 6:57 AM ET
7 http://www.sec.gov. You may read and copy any document the Company files at the website of the SEC referred to above. By Order of the Board of Directors, Danny Sheng Wu Yeung (Chairman and CEO) Dated: October 6, 2023
EX-99.1 to Form 6-K
Jul 18, 2025, 6:38 AM ET
Prenetics Global Limited (the Company)
EX-99.1 to Form 6-K
Jul 17, 2025, 6:53 AM ET
RISK FACTORS RELATED TO OUR BITCOIN TREASURY STRATEGY
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Prenetics Global's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on May 1, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRE.

Revenue growth479.8% · median -20.1%

Gross margin52.8% · median 16.8%

Operating margin-48.1% · median -6.2%

Net margin-40.8% · median -6.5%

Company	Revenue	Growth
LFVN	$182.59M	-20.1%
PRE	$92.39M	+479.8%
INBP	$43.87M	-19.3%
PRPH	$3.85M	-31.2%
BHST	–	–
BGM	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 98
Auditor: Deloitte Touche Tohmatsu
SEC CIK: 1876431

Advertisement
300 × 250